📚 Book Relaunch: The book “Decoding GLP-1” is back on Amazon, now priced at $10, thanks to community advocacy.
⏳ Compounding Update: The FDA has delayed enforcement on 503A pharmacies until a court ruling expected by February 25.
🔬 Fat Cell Research: New findings suggest fat cells may help tailor obesity treatments based on individual profiles.
💊 PBM Concerns: Advocacy for Pharmacy Benefit Manager reform highlights their impact on drug prices and patient access.
📈 Investor Insights: Amalin shows promise in obesity treatment, with new research indicating its effects on appetite and food choices.
🏥 Upcoming Medications: Kagema is anticipated to hit the market in early 2026, alongside new developments from various companies.
🎉 Community Engagement: The podcast encourages listeners to subscribe and support ongoing efforts in obesity medicine discussions
Share this post
On The Pen With Dave Knapp
503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25
503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25
Summary The February 18, 2025 episode of the “On the Pin” podcast covers significant updates in obesity medicine, including the republishing of a key book on GLP-1 medications, ongoing developments in compound medications, and exciting new research into f
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
Appears in episode
On The Pen
Recent Episodes
Share this post